Abstract
Background: Children and adolescents with severe and/or genetic obesity require continuous care and long-term treatment due to the chronic, relapsing, and progressive nature of their disease. Understanding the molecular mechanisms underlying the regulation of hunger, satiety, body weight, and the development of obesity enables a personalized treatment approach. Individualized, multimodal treatment strategies are essential for effective, long-term management of severe and/or genetic obesity in affected children and adolescents. New pharmacological treatments, such as mechanism-based medications for genetic obesity and incretin-based drugs for severe obesity, represent significant advances in chronic weight management and are valuable adjuncts to individualized lifestyle interventions. Summary: This article outlines an innovative, structured care and treatment concept for children and adolescents with severe and/or genetic obesity tailored to their specific needs and requirements. It emphasizes the importance of providing care within specialized treatment centers under the “Chronic Care Model,” in close collaboration with local healthcare providers. Key Message: In order to ensure long-term treatment of children and adolescents with severe and/or genetic obesity, innovative and structured care concepts consisting of individualized, multimodal treatment strategies in specialized treatment centers in collaboration with local healthcare providers are required.
Journal Section:
Invited Mini Review
References
1.
Hampl
SE
, Hassink
SG
, Skinner
AC
, Armstrong
SC
, Barlow
SE
, Bolling
CF
, et al. Executive summary: clinical practice guideline for the evaluation and treatment of children and adolescents with obesity
. Pediatrics
. 2023
;151
(2
):e2022060641
. 2.
Zolotarjova
J
, Ten Velde
G
, Vreugdenhil
ACE
. Effects of multidisciplinary interventions on weight loss and health outcomes in children and adolescents with morbid obesity
. Obes Rev
. 2018
;19
(7
):931
–46
. 3.
Spinelli
A
, Buoncristiano
M
, Kovacs
VA
, Yngve
A
, Spiroski
I
, Obreja
G
, et al. Prevalence of severe obesity among primary school children in 21 European countries
. Obes Facts
. 2019
;12
(2
):244
–58
. 4.
Hales
CM
, Fryar
CD
, Carroll
MD
, Freedman
DS
, Ogden
CL
. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016
. JAMA
. 2018
;319
(16
):1723
–5
. 5.
Geserick
M
, Vogel
M
, Gausche
R
, Lipek
T
, Spielau
U
, Keller
E
, et al. Acceleration of BMI in early childhood and risk of sustained obesity
. N Engl J Med
. 2018
;379
(14
):1303
–12
. 6.
Wabitsch
M
, V Schnurbein
J
, Vollbach
H
, Lennerz
B
, Weyhreter
H
, Wiegand
S
, et al. [Innovative medical care concepts for adolescents with severe obesity]
. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
. 2020
;63
:831
–8
. 7.
Loos
RJF
, Yeo
GSH
. The genetics of obesity: from discovery to biology
. Nat Rev Genet
. 2022
;23
(2
):120
–33
. 8.
Baldini
G
, Phelan
KD
. The melanocortin pathway and control of appetite-progress and therapeutic implications
. J Endocrinol
. 2019
;241
(1
):R1
–33
. 9.
Farooqi
IS
, Wangensteen
T
, Collins
S
, Kimber
W
, Matarese
G
, Keogh
JM
, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor
. N Engl J Med
. 2007
;356
(3
):237
–47
. 10.
Kleinendorst
L
, Massink
MPG
, Cooiman
MI
, Savas
M
, van der Baan-Slootweg
OH
, Roelants
RJ
, et al. Genetic obesity: next-generation sequencing results of 1230 patients with obesity
. J Med Genet
. 2018
;55
(9
):578
–86
. 11.
Courbage
S
, Poitou
C
, Le Beyec-Le Bihan
J
, Karsenty
A
, Lemale
J
, Pelloux
V
, et al. Implication of heterozygous variants in genes of the leptin-melanocortin pathway in severe obesity
. J Clin Endocrinol Metab
. 2021
;106
(10
):2991
–3006
. 12.
Wade
KH
, Lam
BYH
, Melvin
A
, Pan
W
, Corbin
LJ
, Hughes
DA
, et al. Loss-of-function mutations in the melanocortin 4 receptor in a UK birth cohort
. Nat Med
. 2021
;27
(6
):1088
–96
. 13.
Farooqi
IS
, O’Rahilly
S
. The genetics of obesity in humans
. In: Feingold
KR
, Anawalt
B
, Blackman
MR
, Boyce
A
, Chrousos
G
, Corpas
E
, et al, editors. Hrsg. Endotext
. South Dartmouth, MA
: MDText.com, Inc.
; 2000
.14.
Galler
A
, Thönnes
A
, Joas
J
, Joisten
C
, Körner
A
, Reinehr
T
, et al. Clinical characteristics and outcomes of children, adolescents and young adults with overweight or obesity and mental health disorders
. Int J Obes
. 2024
;48
(3
):423
–32
. 15.
Varela
C
, Andrés
A
, Saldaña
C
. The behavioral pathway model to overweight and obesity: coping strategies, eating behaviors and body mass index
. Eat Weight Disord
. 2020
;25
(5
):1277
–83
. 16.
Latner
JD
, Stunkard
AJ
. Getting worse: the stigmatization of obese children
. Obes Res
. 2003
;11
(3
):452
–6
. 17.
Westbury
S
, Oyebode
O
, van Rens
T
, Barber
TM
. Obesity stigma: causes, consequences, and potential solutions
. Curr Obes Rep
. 2023
;12
(1
):10
–23
. 18.
Sarwer
DB
, Polonsky
HM
. The psychosocial burden of obesity
. Endocrinol Metab Clin North Am
. 2016
;45
(3
):677
–88
. 19.
Danielsson
P
, Kowalski
J
, Ekblom
Ö
, Marcus
C
. Response of severely obese children and adolescents to behavioral treatment
. Arch Pediatr Adolesc Med
. 2012
;166
(12
):1103
–8
. 20.
Lennerz
BS
, Moss
A
, von Schnurbein
J
, Bickenbach
A
, Bollow
E
, Brandt
S
, et al. Do adolescents with extreme obesity differ according to previous treatment seeking behavior? The Youth with Extreme obesity Study (YES) cohort
. Int J Obes
. 2019
;43
(1
):103
–15
. 21.
Lister
NB
, Baur
LA
, Felix
JF
, Hill
AJ
, Marcus
C
, Reinehr
T
, et al. Child and adolescent obesity
. Nat Rev Dis Primers
. 2023
;9
(1
):24
. 22.
Colquitt
JL
, Loveman
E
, O'Malley
C
, Azevedo
LB
, Mead
E
, Al-Khudairy
L
, et al. Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in preschool children up to the age of 6 years
. Cochrane Database Syst Rev
. 2016
;3
:CD012105
. 23.
Mead
E
, Brown
T
, Rees
K
, Azevedo
LB
, Whittaker
V
, Jones
D
, et al. Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age of 6 to 11 years
. Cochrane Database Syst Rev
. 2017
;6
:CD012651
. 24.
Al-Khudairy
L
, Loveman
E
, Colquitt
JL
, Mead
E
, Johnson
RE
, Fraser
H
, et al. Diet, physical activity and behavioural interventions for the treatment of overweight or obese adolescents aged 12 to 17 years
. Cochrane Database Syst Rev
. 2017
;6
:CD012691
. 25.
Knop
C
, Singer
V
, Uysal
Y
, Schaefer
A
, Wolters
B
, Reinehr
T
. Extremely obese children respond better than extremely obese adolescents to lifestyle interventions
. Pediatr Obes
. 2015
;10
(1
):7
–14
. 26.
Reinehr
T
, Hebebrand
J
, Friedel
S
, Toschke
AM
, Brumm
H
, Biebermann
H
, et al. Lifestyle intervention in obese children with variations in the melanocortin 4 receptor gene
. Obesity
. 2009
;17
(2
):382
–9
. 27.
Wabitsch
M
, Farooqi
S
, Flück
CE
, Bratina
N
, Mallya
UG
, Stewart
M
, et al. Natural history of obesity due to POMC, PCSK1, and LEPR deficiency and the impact of setmelanotide
. J Endocr Soc
. 2022
;6
:bvac057
. 28.
Sonntag
D
, Ali
S
, De Bock
F
. Lifetime indirect cost of childhood overweight and obesity: a decision analytic model
. Obesity
. 2016
;24
(1
):200
–6
. 29.
Weghuber
D
, Barrett
T
, Barrientos-Pérez
M
, Gies
I
, Hesse
D
, Jeppesen
OK
, et al. Once-weekly Semaglutide in adolescents with obesity
. N Engl J Med
. 2022
;387
(24
):2245
–57
. 30.
Kelly
AS
, Auerbach
P
, Barrientos-Perez
M
, Gies
I
, Hale
PM
, Marcus
C
, et al. A randomized, controlled trial of Liraglutide for adolescents with obesity
. N Engl J Med
. 2020
;382
(22
):2117
–28
. 31.
Fox
CK
, Barrientos-Pérez
M
, Bomberg
EM
, Dcruz
J
, Gies
I
, Harder-Lauridsen
NM
, et al. Liraglutide for children 6 to <12 years of age with obesity - a randomized trial
. N Engl J Med
. 2024
;392
(6
):555
–65
. 32.
Iepsen
EW
, Zhang
J
, Thomsen
HS
, Hansen
EL
, Hollensted
M
, Madsbad
S
, et al. Patients with obesity caused by melanocortin-4 receptor mutations can Be treated with a glucagon-like peptide-1 receptor agonist
. Cell Metab
. 2018
;28
(1
):23
–32.e3
. 33.
Welling
MS
, de Groot
CJ
, Kleinendorst
L
, van der Voorn
B
, Burgerhart
JS
, van der Valk
ES
, et al. Effects of glucagon-like peptide-1 analogue treatment in genetic obesity: a case series
. Clin Obes
. 2021
;11
(6
):e12481
. 34.
Iepsen
EW
, Have
CT
, Veedfald
S
, Madsbad
S
, Holst
JJ
, Grarup
N
, et al. GLP-1 receptor agonist treatment in morbid obesity and type 2 diabetes due to pathogenic homozygous melanocortin-4 receptor mutation: a case report
. Cell Rep Med
. 2020
;1
:100006
. 35.
Kusminski
CM
, Perez-Tilve
D
, Müller
TD
et al. Transforming obesity: The advancement of multi-receptor drugs
. Cell
. 2024
;187
(15
):3829
–53
. 36.
Farooqi
IS
, Matarese
G
, Lord
GM
, Keogh
JM
, Lawrence
E
, Agwu
C
, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency
. J Clin Investig
. 2002
;110
(8
):1093
–103
. 37.
Clément
K
, van den Akker
E
, Argente
J
, Bahm
A
, Chung
WK
, Connors
H
, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
. Lancet Diabetes Endocrinol
. 2020
;8
(12
):960
–70
. 38.
Haqq
AM
, Chung
WK
, Dollfus
H
, Haws
RM
, Martos-Moreno
GÁ
, Poitou
C
, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period
. Lancet Diabetes Endocrinol
. 2022
;10
(12
):859
–68
. 39.
Inge
TH
, Courcoulas
AP
, Jenkins
TM
, Michalsky
MP
, Helmrath
MA
, Brandt
ML
, et al. Weight loss and health status 3 years after bariatric surgery in adolescents
. N Engl J Med
. 2016
;374
(2
):113
–23
. 40.
Olbers
T
, Beamish
AJ
, Gronowitz
E
, Flodmark
CE
, Dahlgren
J
, Bruze
G
, et al. Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish nationwide study
. Lancet Diabetes Endocrinol
. 2017
;5
(3
):174
–83
. 41.
Brandt
S
, Lennerz
BS
, Wiegand
S
, Schirmer
M
, Kleger
P
, Weyhreter
H
, et al. Twelve-month outcomes after metabolic and bariatric surgery among youths participating in a structured preparation and follow-up program: results of the youth with extreme obesity study
. Obes Facts
. 2024
;17
(1
):59
–71
. 42.
Cooiman
MI
, Kleinendorst
L
, Aarts
EO
, Janssen
IMC
, van Amstel
HKP
, Blakemore
AI
, et al. Genetic obesity and bariatric surgery outcome in 1014 patients with morbid obesity
. Obes Surg
. 2020
;30
(2
):470
–7
. 43.
Poitou
C
, Puder
L
, Dubern
B
, Krabusch
P
, Genser
L
, Wiegand
S
, et al. Long-term outcomes of bariatric surgery in patients with bi-allelic mutations in the POMC, LEPR, and MC4R genes
. Surg Obes Relat Dis
. 2021
;17
(8
):1449
–56
. 44.
Zorn
S
, Schirmer
M
, von Schnurbein
J
, Brandt
S
, Göpel
E
, Stein
R
, et al. Versorgungskonzepte für Kinder und Jugendliche mit extremer und/oder genetischer Adipositas
. Adipositas – Ursachen, Folgeerkrankungen, Therapie
. 2024
;18
(02
):71
–80
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
